Participation in clinical trials depends on several factors, including (but not limited to) your age, your other medical conditions, current medications, and willingness to participate.

All information is strictly confidential and is never rented or sold.

Clinical Trials

The Gemini Trials: NCT04410978 & NCT04410991

  • Relapsing Multiple Sclerosis (RMS)
  • ages 18 to 55 years

GEMINI I and II are phase III clinical trials that will assess the efficacy and safety of tolebrutinib, the investigational study drug, on relapse rates in participants with Relapsing Multiple Sclerosis (RMS).

Participants will be randomly assigned (by chance like flipping a coin) to receive tolebrutinib, or Aubagio® (teriflunomide) in a 1:1 ratio. This means one half of participants will take tolebrutinib and the other half Aubagio® (teriflunomide).

The primary objective of these trials is to compare the average number of relapses per year between the two groups.

Additional objectives include assessment of worsening or improvement of disability as measured by EDSS score (Expanded Disability Status Scale), disease activity on MRI brain, cognitive ability (learning, reasoning…), and quality of life, as well as the safety and tolerability of the investigational study drug.

For additional details about Gemini trials you can visit ClinicalTrials.gov:
Gemini I
Gemini II

The Hercules Trial: NCT04411641

  • Secondary Progressive MS, Non-Relapsing (nrSPMS)
  • ages 18 to 60 years

HERCULES is a phase III clinical trial that will assess the efficacy and safety of tolebrutinib, the investigational study drug, in delaying disability progression in participants with non-relapsing Secondary Progressive Multiple Sclerosis (nrSPMS).

Participants will be randomly assigned (by chance like flipping a coin) to receive tolebrutinib or placebo (like a sugar pill) in a 2:1 ratio. This means two thirds of participants will take tolebrutinib and the other third a placebo.

The primary objective of this trial is to compare the time to onset of disability progression, defined via the EDSS score (Expanded Disability Status Scale), which persists for six months between the 2 groups.

Additional objectives include assessment of lesions visible on MRI scans, progression or improvement of disability, the ability to learn and process information, and quality of life, as well as the safety and tolerability of the investigational study medication.

For additional details about the Hercules trial you can visit ClinicalTrials.gov

The Perseus Trial: NCT04458051

  • Primary Progressive Multiple Sclerosis (PPMS)
  • ages 18 to 55 years

PERSEUS is a phase III clinical trial that will assess the efficacy and safety of tolebrutinib, the investigational study drug, in delaying disability progression in participants with Primary Progressive Multiple Sclerosis (PPMS).

Participants will be randomly assigned (by chance like flipping a coin) to receive tolebrutinib or placebo (like a sugar pill) in a 2:1 ratio. This means two thirds of participants will take tolebrutinib and the other third a placebo.

The primary objective of this trial is to compare the time to onset of disability progression, defined via the EDSS score (Expanded Disability Status Scale), which persists for six months between the 2 treatment groups.

Additional objectives include assessment of lesions visible on MRI scans, progression or improvement of disability, the ability to learn and process information, and quality of life, as well as the safety and tolerability of the investigational study medication.

For additional details about the Perseus trial you can visit ClinicalTrials.gov